Lung Cancer

Here is a list of the recent trial initiations that occurred within the cancer space in May.
 

In the 2020 Spring issue of CURE^® Magazine hear from the experts on how to best keep up with the evolving situation of the COVID-19 pandemic.
 

The Food and Drug Administration approved the combination of Opdivo and Yervoy with 2 cycles of chemotherapy as a first-line treatment for certain patients with metastatic non-small cell lung cancer.
 

The Food and Drug Administration approved Alunbrig for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

From Johnson & Johnson discontinuing their talc-based baby powder in the U.S. and Canada after numerous lawsuits that cited the talc, a mineral similar to asbestos, caused cancer, to the ramifications of delayed cancer surgeries being felt by patients, here’s everything happening in the cancer space this week.

The Food and Drug Administration continues to approve cancer therapies amid the COVID-19 pandemic. Here are five approvals that patients with cancer may have missed.
 

Tecentriq is approved as an initial treatment for non-small cell lung cancer that has spread and expresses the protein PD-L1 but does not have alterations in the EGFR or ALK genes.
 

The Food and Drug Administration has approved the combination of Opdivo-Yervoy immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer that do not have certain genomic tumor aberrations.
 

“It’s never too late to quit smoking,” is the primary message of a new study that shows those who quit smoking have a survival benefit prior to a lung cancer diagnosis.    

The Food and Drug Administration approved the first therapy to treat cancers with rearranged during transfection, or RET, gene alterations.